Atopic Dermatitis

Jonathan M. Spergel, MD, PhD, FACAAI discusses what there is to look forward to at the ACAAI conference and what he's highlighting at the event.

In this episode of DermView, Adelaide Hebert, MD, highlights both emollients and moisturizers. She also talks about bathing and how often a child should bathe if they have eczema.

Investigators noted the treatment method was well tolerated in patients who could not safely use oral cyclosporine.

Investigators suggested the prevention of exposure during pregnancy could help control atopic dermatitis and other potential allergies in pediatric populations.

Patients treated with the monoclonal antibody had increased incidences of conjunctivitis, though many of these incidences were considered mild and were resolved by the end of the study.

Investigators recommended a treatment course of at least 1-2 months with medium strength to potent topical corticosteroids should be considered before dupilumab discontinuation in affected children and adolescents.

In this episode of DermView, Adelaide Hebert, MD, explains the clinical manifestations of eczema, how the chronic the condition is, and the benefits of using ceramide cream for management.

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

In this week’s Pointers with Dr Portela, the 208SkinDoc explains what keratosis pilaris is and whether or not it can be cured.

In this episode of DermView, Adelaide Hebert, MD, explains how eczema can lead to growth issues in pediatric patients, how environmental factors may play a role in flare ups, and more.

In this exclusive video interview with Dermatology Times®, Andrew Blauvelt, MD, MBA, discusses the newest phase 3 clinical data on investigational tralokinumab as a potential treatment option in atopic dermatitis.

Amgen and Kyowa Kirin announce positive study data from their phase 2 trial of AMG 451/KHK4083.

Nemolizumab phase 2 clinical trial data for patients with prurigo nodularis and atopic dermatitis was recently released at the EADV.

How are atopic dermatitis and out of pocket health care expenses related? This study aimed to find out.

A recent study in JAMA Dermatology investigated the possible association of atopic dermatitis and mental health outcomes across childhood.

In this episode, Marc Serota, MD, discusses his research regarding type 2 inflammation, the future of treating it as 1 condition or 2, and more!

Delgocitinib is the first and only topical JAK/STAT pathway inhibitor in Japan, and recent data suggests it is effective in the management of atopic dermatitis.

Two poster presentations at the EADV 30th annual conference showed the efficacy of roflumilast foam for nonsteroidal treatment of psoriasis or seborrheic dermatitis.

Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.

At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.

New therapies raise patient expectations for fast efficacy, lower costs, and fewer adverse effects.

Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.